Abstract:The equilibrium between histone acetylation and deacetylation plays an important role in cancer initiation and progression. The histone deacetylases (HDACs) are a class of key regulators of gene expression that enzymatically remove an acetyl moiety from acetylated lysine ε-amino groups on histone tails. Therefore, HDAC inhibitors have recently emerged as a promising strategy for cancer therapy and several pan-HDAC inhibitors have globally been approved for clinical use. In the present study, we designed and synthesized a series of substituted indole-based hydroxamic acid derivatives that exhibited potent anti-proliferative activities in various tumor cell lines. Among the compounds tested, compound 4o, was found to be among the most potent in the inhibition of HDAC1 (half maximal inhibitory concentration, IC50 = 1.16 nM) and HDAC6 (IC50 = 2.30 nM). It also exhibited excellent in vitro anti-tumor proliferation activity. Additionally, compound 4o effectively increased the acetylation of histone H3 in a dose-dependent manner and inhibited cell proliferation by inducing cell cycle arrest and apoptosis. Moreover, compound 4o remarkably blocked colony formation in HCT116 cancer cells. Based on its favorable in vitro profile, compound 4o was further evaluated in an HCT116 xenograft mouse model, in which it demonstrated better in vivo efficacy than the clinically used HDAC inhibitor, suberanilohydroxamic acid. Interestingly, compound 4k was found to have a preference for the inhibition of HDAC6, with IC50 values of 115.20 and 5.29 nM against HDAC1 and HDAC6, respectively.

Discovery of 1,2,4-Oxadiazole-containing Hydroxamic Acid Derivatives As Histone Deacetylase Inhibitors Potential Application in Cancer Therapy.

Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors

Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities

Development of Hydroxamate-Based Histone Deacetylase Inhibitors Containing 1,2,4-Oxadiazole Moiety Core with Antitumor Activities.

Synthesis and anticancer activity of novel histone deacetylase inhibitors that inhibit autophagy and induce apoptosis

Development of tetrahydroisoquinoline-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities.

Design, synthesis and biological evaluation of coumarin-based N-hydroxycinnamamide derivatives as novel histone deacetylase inhibitors with anticancer activities

Design, synthesis and preliminary bioactivity studies of 1,3,4-thiadiazole hydroxamic acid derivatives as novel histone deacetylase inhibitors.

Discovery of quinazolinyl-containing benzamides derivatives as novel HDAC1 inhibitors with in vitro and in vivo antitumor activities

Development of Coumarin-Based Hydroxamates as Histone Deacetylase Inhibitors with Antitumor Activities

Synthesis and biological evaluation of triazol-4-ylphenyl-bearing histone deacetylase inhibitors as anticancer agents.

Novel N-hydroxybenzamide Histone Deacetylase Inhibitors As Potential Anti-Cancer Agents.

A hybrid of thiazolidinone with the hydroxamate scaffold for developing novel histone deacetylase inhibitors with antitumor activities

Discovery of a Tetrahydroisoquinoline-Based Hydroxamic Acid Derivative (Zyj-34C) As Histone Deacetylase Inhibitor with Potent Oral Antitumor Activities.

Design, synthesis and bioevaluation of novel N-heterocyclic hydroxamic acids as histone deacetylase inhibitors and their antitumor activity study

Discovery and Preliminary Evaluation of 2-Aminobenzamide and Hydroxamate Derivatives Containing 1,2,4-Oxadiazole Moiety As Potent Histone Deacetylase Inhibitors.

Design, Synthesis and Biological Evaluation of 4-Anilinothieno[2,3-d]pyrimidine-based Hydroxamic Acid Derivatives As Novel Histone Deacetylase Inhibitors.

Design and optimization of novel Tetrahydro-β-carboline-based HDAC inhibitors with potent activities against tumor cell growth and metastasis

Discovery of A Series of Hydroximic Acid Derivatives As Potent Histone Deacetylase Inhibitors

[Design, Synthesis, and Biological Activities of Histone Deacetylase Inhibitors with Diketo Ester As Zinc Binding Group].

Development of N-Hydroxycinnamamide-Based Hdac Inhibitors with Improved Hdac Inhibitory Activity and in Vitro Antitumor Activity